Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: Association of interleukin 12 elevation with spontaneous regression of skin sclerosis

Journal of Rheumatology

Volumn 33, Issue 2, 2006, Pages 275-284

  Matsushita, Takashi ^a   Hasegawa, Minoru ^a   Hamaguchi, Yasuhito ^a   Takehara, Kazuhiko ^a   Sato, Shinichi ^b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Interleukin 12; Systemic sclerosis; Th1; Th2

Indexed keywords

CORTICOSTEROID; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PENICILLAMINE; PREDNISOLONE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL;

ADULT; CHEMOKINE CCL2; FEMALE; FIBROSIS; GENE EXPRESSION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REMISSION, SPONTANEOUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 32144454167     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
2. Fiocco U, Rosada M, Cozzi L, et al. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis 1993;52:272-7.
3. Chizzolini C. T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 1999;21:431-50.
4. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
5. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
6. Famularo G, Procopio A, Giacomelli R, et al. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 1990;81:368-72.
7. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328-32.
8. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308-13.
9. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology Oxford 1999;38:612-7.
10. Mavalia C, Scaletti C, Romagnani P, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
11. Giacomelli R, Cipriani P, Lattanzio R, et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997;108:42-6.
12. Sato S, Hanakawa H, Hasegawa M, et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000;27:2838-42.
13. Giacomelli R, Cipriani P, Fulminis A, et al. Circulating γ/Δ T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 2001;125:310-5.
14. Fujii H, Hasegawa M, Takehara K, Mukaida N. Sato S. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 2002:130:548-56.
15. Majumdar S, Li D, Ansari T, et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999;14:251-7.
16. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
17. Black C, Dieppe P, Huskisson T, Hart FD. Regressive systemic sclerosis. Ann Rheum Dis 1986;45:384-8.
18. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
19. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
20. LeRoy EC, Krieg T, Black C, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
21. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
22. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
23. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diag 2001;3:55-61.
24. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000;404:407-11.
25. Sad S, Mosmann TR. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol 1994;153:3514-22.
26. Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 2002;46:1703-13.
27. Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000;275:30226-31.
28. Chizzolini C, Parel Y, De Luca C, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 2003;48:2593-604.
29. Rosenbloom J, Feldman G, Freundlich B, Jimenez SA. Inhibition of excessive scleroderma fibroblast collagen production by recombinant γ-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum 1986;29:851-6.
30. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS. A multicenter trial of recombinant human interferon γ in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996;23:654-8.
31. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-γ in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998;139:639-48.
32. Marth T, Strober W, Seder RA, Kelsall BL. Regulation of transforming growth factor-β production by interleukin-12. Eur J Immunol 1997;27:1213-20.
33. Tsuji-Yamada J, Nakazawa M, Takahashi K, et al. Effect of IL-12 encoding plasmid administration on tight-skin mouse. Biochem Biophys Res Commun 2001;280:707-12.
34. Gillery P, Fertin C, Nicolas JF, et al. Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett 1992;302:231-4.
35. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686-92.
36. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253-60.
37. Feghali CA, Host KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
38. Saito E, Fujimoto M, Hasegawa M, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002;109:1453-62.
39. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
40. Reitamo S, Remitz A, Tamai K, Uitto I. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 1994;94:2489-92.
41. Huaux F, Louahed J, Hudspith B, et al. Role of interleukin-10 in the lung response to silica in mice. Am J Respir Cell Mol Biol 1998;18:51-9.
42. Louis H, Le Moine A, Quertinmont E, et al. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology 2000;31:381-90.
43. Veale DJ, Fearon UM, Henshaw K, et al. Clinical and laboratory measures of disease activity in systemic sclerosis [abstract]. Arthritis Rheum 2001;Suppl 44:S327.
44. Atamas SP, Yurovsky VV, Wise R, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168-78.
45. Spinozzi F, Agea E, Russano A, et al. Th2-type cytokines and the Fas way to pulmonary fibrosis: comment on the article by Atamas et al [letter]. Arthritis Rheum 2000;43:236-8.
46. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (MCP-1, MTP-1a, and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-65.
47. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665-78.
48. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510-6.
49. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor β1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994;37:278-88.
50. Maeda H, Shiraishi A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996;156:73-8.
51. Takahashi K, Miyake S, Kondo T. et al. Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 2001;107:R23-R9.